GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Quantum BioPharma Ltd (NAS:QNTM) » Definitions » Quality Rank

QNTM (Quantum BioPharma) Quality Rank


View and export this data going back to 2018. Start your Free Trial

What is Quantum BioPharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Quantum BioPharma Quality Rank Related Terms

Thank you for viewing the detailed overview of Quantum BioPharma's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Quantum BioPharma Business Description

Traded in Other Exchanges
Address
199 Bay Street, Suite 4000, Toronto, ON, CAN, M5L 1A9
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.